Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8534574 | 0.93 | PIK3CD (0.51) | GPR119NPBWR1MCHR1 | |
| SCHEMBL8534703 | 0.88 | USP30 (0.45) | GPR119 | |
| SCHEMBL23311785 | 0.87 | GPR119 (0.57) | GPR119NPBWR1MCHR1CHEK2 | |
| SCHEMBL17560148 | 0.87 | GPR119 (0.57) | GPR119NPBWR1MCHR1CHEK2ALDH1A1 | |
| SCHEMBL19504087 | 0.86 | GPR119 (0.54) | GPR119NPBWR1MCHR1CHEK2 | |
| SCHEMBL20303382 | 0.86 | GPR119 (0.57) | GPR119NPBWR1MCHR1CHEK2ALDH1A1 | |
| SCHEMBL17906592 | 0.86 | GPR119 (0.56) | GPR119NPBWR1MCHR1CHEK2ALDH1A1 | |
| SCHEMBL2488375 | 0.86 | GPR119 (0.56) | GPR119NPBWR1MCHR1CHEK2ALDH1A1 | |
| SCHEMBL30427192 | 0.86 | GPR119 (0.56) | GPR119NPBWR1MCHR1CHEK2ALDH1A1 | |
| SCHEMBL1698685 | 0.85 | GPR119 (0.57) | GPR119NPBWR1MCHR1CHEK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117377665-A | PARP7 inhibitor and application thereof | 北京华森英诺生物科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| WO-2023020479-A1 | PARP7 INHIBITOR AND APPLICATION THEREOF | 重庆华森制药股份有限公司 | 2023-02-23 | — | — | WO | disclosed |
| EP-3189059-B1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2023-02-22 | — | — | EP | disclosed |
| US-10183952-B2 | Thienopyrroles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-01-22 | — | — | US | disclosed |
| US-20170260197-A1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2017-09-14 | — | — | US | disclosed |
| EP-3189059-A2 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2017-07-12 | — | — | EP | disclosed |
| EP-3145912-A1 | BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-9382222-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382222-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2016034946-A2 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2016-03-10 | — | — | WO | disclosed |
| US-9000175-B2 | Bicyclic GPR119 modulators | LUPIN LIMITED (IN) | 2015-04-07 | — | — | US | disclosed |
| WO-2014090712-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014090712-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| US-20140163024-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163024-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2643311-A1 | BICYCLIC GPR119 MODULATORS | Lupin Limited (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | US | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163024-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | GPR119 388/4885NPBWR1 250/4885MCHR1 291/4885 |
| US-10183952-B2 | Thienopyrroles as histone demethylase inhibitors | KDM1A, KDM1B, KDM3A | GPR119 75/4885NPBWR1 2469/4885MCHR1 2051/4885 |
| US-20170260197-A1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | KDM1A, KDM1B, KDM3A | GPR119 75/4885NPBWR1 2469/4885MCHR1 2051/4885 |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | GPR119 1336/4885NPBWR1 2278/4885MCHR1 2946/4885 |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | GPR119, GPR180, GPBAR1 | GPR119 1/4885NPBWR1 265/4885MCHR1 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.